Olatorepatide

Status

In trials. Investigational. Developed by Hansoh Pharmaceutical and licensed to Regeneron outside Greater China (June 2025). A new-drug application for long-term weight management was accepted for review by China's NMPA in June 2026 — the furthest along of its generation; no approval is listed in this entry's sources yet.

What it is

A GLP-1/GIP dual agonist — the same two-receptor design as tirzepatide, built independently by a Chinese developer and now carrying Regeneron's Western ambitions.

What published research measured

A phase 3 trial in Chinese adults with overweight or obesity reported mean weight loss of up to 19.3% at 48 weeks, with low rates of gastrointestinal adverse events and discontinuation (company announcement, March 2026). The weight-management NDA was accepted for review by China's regulator in June 2026. Topline data again, not a peer-reviewed publication.

Source

Hansoh Pharmaceutical announcements, 2026; Regeneron licensing announcement, June 2025; ClinicalTrials.gov NCT06839664

Sources

• ClinicalTrials.gov NCT06839664